CMPS Nov 2024 10.000 put
| Previous Close | 4.1000 |
| Open | 4.1000 |
| Bid | 3.8000 |
| Ask | 4.2000 |
| Strike | 10.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 4.1000 - 4.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 28 |
Washington PostAfter FDA setback, psychedelic drugmakers distance themselves from a pioneer
CORRECTION: A previous version of this article misstated the position of Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies. Doblin has said MDMA could help reduce the world’s trauma, not eliminate it. Originally moved June 8. - - - Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. Developers of mind-bending drugs for medical use are distancing themselves from the first company to seek regulatory approval
Insider MonkeyCOMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript May 11, 2024 COMPASS Pathways plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to the COMPASS Pathways’ First Quarter 2024 Earning Investor Call […]
GlobeNewswireCompass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head of R&DCompass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8
